Leerink Partnrs Research Analysts Decrease Earnings Estimates for LENZ Therapeutics, Inc. (NASDAQ:LENZ)

LENZ Therapeutics, Inc. (NASDAQ:LENZ) – Stock analysts at Leerink Partnrs decreased their Q3 2024 EPS estimates for shares of LENZ Therapeutics in a research report issued to clients and investors on Wednesday, August 14th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings of ($0.45) per share for the quarter, down from their previous forecast of ($0.32). The consensus estimate for LENZ Therapeutics’ current full-year earnings is ($3.06) per share. Leerink Partnrs also issued estimates for LENZ Therapeutics’ Q4 2024 earnings at ($0.52) EPS, FY2024 earnings at ($4.90) EPS, FY2025 earnings at ($3.00) EPS, FY2026 earnings at ($2.10) EPS, FY2027 earnings at ($0.20) EPS and FY2028 earnings at ($2.00) EPS.

Several other equities research analysts have also commented on LENZ. Piper Sandler restated an “overweight” rating and issued a $36.00 price target on shares of LENZ Therapeutics in a report on Thursday, August 15th. HC Wainwright assumed coverage on shares of LENZ Therapeutics in a report on Monday, August 12th. They issued a “buy” rating and a $38.00 price target for the company. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, LENZ Therapeutics has a consensus rating of “Buy” and an average target price of $35.00.

LENZ Therapeutics Price Performance

LENZ Therapeutics stock opened at $22.50 on Monday. LENZ Therapeutics has a 1 year low of $14.07 and a 1 year high of $29.82. The firm has a 50-day moving average of $20.90.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Deerfield Management Company L.P. Series C purchased a new stake in shares of LENZ Therapeutics in the 2nd quarter valued at $300,000. Squarepoint Ops LLC purchased a new stake in shares of LENZ Therapeutics in the 2nd quarter valued at $181,000. Marshall Wace LLP purchased a new stake in shares of LENZ Therapeutics in the 2nd quarter valued at $390,000. Renaissance Technologies LLC boosted its holdings in shares of LENZ Therapeutics by 28.4% in the 2nd quarter. Renaissance Technologies LLC now owns 60,166 shares of the company’s stock valued at $1,040,000 after acquiring an additional 13,300 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in LENZ Therapeutics by 58.0% during the second quarter. Dimensional Fund Advisors LP now owns 37,190 shares of the company’s stock worth $644,000 after buying an additional 13,653 shares in the last quarter. Institutional investors own 54.32% of the company’s stock.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.